USD 2.16
(-8.86%)
Year | Total Debt | Total Debt Growth |
---|---|---|
2023 | 41.26 Million USD | 3.7% |
2022 | 39.79 Million USD | 155.8% |
2021 | 15.55 Million USD | -1.98% |
2020 | 15.87 Million USD | 44.26% |
2019 | 11 Million USD | 1991.63% |
2018 | 526 Thousand USD | -40.5% |
2017 | 884 Thousand USD | 64.31% |
2016 | 538 Thousand USD | -36.56% |
2015 | 848 Thousand USD | 0.0% |
2014 | - USD | 0.0% |
2013 | - USD | -100.0% |
2012 | 1.43 Million USD | 590.67% |
2011 | 207.37 Thousand USD | 3798.11% |
2010 | 5319.86 USD | 0.0% |
2009 | - USD | -100.0% |
2008 | 1392.10 USD | -68.17% |
2007 | 4374.01 USD | -33.72% |
2006 | 6599.00 USD | -57.14% |
2005 | 15.39 Thousand USD | -48.37% |
2004 | 29.82 Thousand USD | 0.0% |
Year | Total Debt | Total Debt Growth |
---|---|---|
2024 Q1 | 41.09 Million USD | -0.4% |
2024 Q2 | 56.66 Million USD | 37.87% |
2023 Q3 | 40.73 Million USD | 0.35% |
2023 Q1 | 39.58 Million USD | -0.53% |
2023 Q2 | 40.58 Million USD | 2.54% |
2023 FY | 41.26 Million USD | 3.7% |
2023 Q4 | 41.26 Million USD | 1.31% |
2022 Q4 | 39.79 Million USD | 3.86% |
2022 Q2 | 14.37 Million USD | 61.84% |
2022 Q3 | 38.31 Million USD | 166.53% |
2022 FY | 39.79 Million USD | 155.8% |
2022 Q1 | 8.88 Million USD | -42.9% |
2021 Q2 | 15.13 Million USD | 289.23% |
2021 Q4 | 15.55 Million USD | 300.0% |
2021 FY | 15.55 Million USD | -1.98% |
2021 Q1 | 3.88 Million USD | -75.5% |
2021 Q3 | 3.88 Million USD | -74.31% |
2020 FY | 15.87 Million USD | 44.26% |
2020 Q1 | 10.21 Million USD | -7.12% |
2020 Q2 | 10.83 Million USD | 6.02% |
2020 Q3 | 15.11 Million USD | 39.51% |
2020 Q4 | 15.87 Million USD | 5.01% |
2019 Q1 | 1.11 Million USD | 112.74% |
2019 FY | 11 Million USD | 1991.63% |
2019 Q2 | 1.82 Million USD | 63.36% |
2019 Q4 | 11 Million USD | 6.28% |
2019 Q3 | 10.35 Million USD | 466.3% |
2018 Q2 | 690 Thousand USD | 0.0% |
2018 Q3 | 409 Thousand USD | -40.72% |
2018 Q4 | 526 Thousand USD | 28.61% |
2018 FY | 526 Thousand USD | -40.5% |
2018 Q1 | 690 Thousand USD | -21.95% |
2017 Q4 | 884 Thousand USD | 23.81% |
2017 Q3 | 714 Thousand USD | 32.22% |
2017 Q2 | 540 Thousand USD | 0.0% |
2017 Q1 | 540 Thousand USD | 0.37% |
2017 FY | 884 Thousand USD | 64.31% |
2016 Q3 | 538 Thousand USD | -18.98% |
2016 Q1 | 664 Thousand USD | -21.7% |
2016 Q4 | 538 Thousand USD | 0.0% |
2016 FY | 538 Thousand USD | -36.56% |
2016 Q2 | 664 Thousand USD | 0.0% |
2015 Q1 | 303 Thousand USD | 0.0% |
2015 Q3 | 848 Thousand USD | 179.87% |
2015 FY | 848 Thousand USD | 0.0% |
2015 Q4 | 848 Thousand USD | 0.0% |
2015 Q2 | 303 Thousand USD | 0.0% |
2014 Q3 | - USD | 0.0% |
2014 Q2 | - USD | 0.0% |
2014 Q1 | - USD | 0.0% |
2014 Q4 | - USD | 0.0% |
2014 FY | - USD | 0.0% |
2013 FY | - USD | -100.0% |
2013 Q4 | - USD | 0.0% |
2013 Q3 | - USD | 0.0% |
2013 Q2 | - USD | 0.0% |
2013 Q1 | - USD | -100.0% |
2012 Q1 | 358.06 Thousand USD | 72.67% |
2012 FY | 1.43 Million USD | 590.67% |
2012 Q4 | 1.43 Million USD | 300.0% |
2012 Q3 | 358.06 Thousand USD | 528.53% |
2012 Q2 | 56.96 Thousand USD | -84.09% |
2011 Q4 | 207.37 Thousand USD | 300.0% |
2011 Q2 | 2895.40 USD | -94.42% |
2011 FY | 207.37 Thousand USD | 3798.11% |
2011 Q1 | 51.84 Thousand USD | 874.52% |
2011 Q3 | 51.84 Thousand USD | 1690.53% |
2010 Q3 | 1329.96 USD | 0.0% |
2010 Q1 | 1329.96 USD | 0.0% |
2010 Q2 | - USD | -100.0% |
2010 FY | 5319.86 USD | 0.0% |
2010 Q4 | 5319.86 USD | 300.0% |
2009 Q3 | - USD | 0.0% |
2009 Q4 | - USD | 0.0% |
2009 FY | - USD | -100.0% |
2009 Q1 | - USD | -100.0% |
2009 Q2 | - USD | 0.0% |
2008 Q4 | 348.02 USD | 0.0% |
2008 Q1 | 348.02 USD | -68.17% |
2008 Q3 | 348.02 USD | 0.0% |
2008 Q2 | 348.02 USD | 0.0% |
2008 FY | 1392.10 USD | -68.17% |
2007 Q4 | 1093.50 USD | 0.0% |
2007 Q2 | 1093.50 USD | 0.0% |
2007 Q3 | 1093.50 USD | 0.0% |
2007 FY | 4374.01 USD | -33.72% |
2007 Q1 | 1093.50 USD | -33.72% |
2006 Q2 | 1649.75 USD | 0.0% |
2006 Q3 | 1649.75 USD | 0.0% |
2006 Q1 | 1649.75 USD | -57.14% |
2006 FY | 6599.00 USD | -57.14% |
2006 Q4 | 1649.75 USD | 0.0% |
2005 FY | 15.39 Thousand USD | -48.37% |
2005 Q2 | 3849.30 USD | 0.0% |
2005 Q4 | 3849.30 USD | 0.0% |
2005 Q3 | 3849.30 USD | 0.0% |
2005 Q1 | 3849.30 USD | -48.37% |
2004 Q1 | 7455.81 USD | 0.0% |
2004 FY | 29.82 Thousand USD | 0.0% |
2004 Q3 | 7455.81 USD | 0.0% |
2004 Q4 | 7455.81 USD | 0.0% |
2004 Q2 | 7455.81 USD | 0.0% |
Name | Total Debt | Total Debt Difference |
---|---|---|
Bionano Genomics, Inc. | 87.94 Million USD | 53.08% |
Prenetics Global Limited | 2.36 Million USD | -1641.589% |
Star Equity Holdings, Inc. | 3.6 Million USD | -1043.392% |
CareDx, Inc | 34.22 Million USD | -20.584% |
Exact Sciences Corporation | 2.55 Billion USD | 98.385% |
Exagen Inc. | 23.72 Million USD | -73.96% |
Inotiv, Inc. | 417.64 Million USD | 90.12% |
Guardant Health, Inc. | 1.35 Billion USD | 96.952% |
Biodesix, Inc. | 60.69 Million USD | 32.008% |
BioNexus Gene Lab Corp. | 133.39 Thousand USD | -30834.443% |
Precipio, Inc. | 1.11 Million USD | -3597.581% |
iSpecimen Inc. | 196.24 Thousand USD | -20927.394% |
Natera, Inc. | 441.99 Million USD | 90.664% |
Aspira Women's Health Inc. | 2.26 Million USD | -1721.05% |
Standard BioTools Inc. | 98.21 Million USD | 57.983% |
23andMe Holding Co. | 76.51 Million USD | 46.069% |
Castle Biosciences, Inc. | 15.31 Million USD | -169.53% |
Personalis, Inc. | 48.96 Million USD | 15.72% |
Aclaris Therapeutics, Inc. | 426 Thousand USD | -9586.62% |
Applied DNA Sciences, Inc. | 1.23 Million USD | -3233.845% |
OpGen, Inc. | 13.04 Million USD | -216.359% |
T2 Biosystems, Inc. | 49.49 Million USD | 16.633% |
Myriad Genetics, Inc. | 145 Million USD | 71.541% |
ICON Public Limited Company | 3.93 Billion USD | 98.952% |
NeoGenomics, Inc. | 611.67 Million USD | 93.254% |
Star Equity Holdings, Inc. | 3.6 Million USD | -1043.392% |
IDEXX Laboratories, Inc. | 947.88 Million USD | 95.647% |
RadNet, Inc. | 1.49 Billion USD | 97.233% |
Psychemedics Corporation | 2.29 Million USD | -1695.692% |
Illumina, Inc. | 2.26 Billion USD | 98.176% |
Check-Cap Ltd. | - USD | -Infinity% |
Twist Bioscience Corporation | 94.06 Million USD | 56.133% |
DarioHealth Corp. | 29.54 Million USD | -39.687% |
Fulgent Genetics, Inc. | 14.9 Million USD | -176.816% |
Sera Prognostics, Inc. | 1.85 Million USD | -2120.936% |
ENDRA Life Sciences Inc. | 394.4 Thousand USD | -10362.649% |
OPKO Health, Inc. | 326.56 Million USD | 87.364% |
Medpace Holdings, Inc. | 142.12 Million USD | 70.965% |
Neogen Corporation | 906.23 Million USD | 95.447% |
Intelligent Bio Solutions Inc. | 871.44 Thousand USD | -4635.266% |
Prenetics Global Limited | 2.36 Million USD | -1641.589% |
Mainz Biomed B.V. | 7.42 Million USD | -456.074% |
bioAffinity Technologies, Inc. | 1.57 Million USD | -2513.961% |
Trinity Biotech plc | 67.42 Million USD | 38.8% |
Neuronetics, Inc. | 62.47 Million USD | 33.949% |
Sotera Health Company | 2.32 Billion USD | 98.227% |
bioAffinity Technologies, Inc. | 1.57 Million USD | -2513.961% |